Analysts forecast that Opko Health Inc. (NASDAQ:OPK) will post ($0.09) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Opko Health’s earnings, with estimates ranging from ($0.10) to ($0.07). Opko Health posted earnings per share of ($0.12) during the same quarter last year, which suggests a positive year-over-year growth rate of 25%. The business is expected to report its next earnings results on Thursday, March 7th.
On average, analysts expect that Opko Health will report full year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.24) to ($0.20). For the next year, analysts anticipate that the business will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.34) to ($0.17). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Opko Health.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Opko Health had a negative return on equity of 8.68% and a negative net margin of 30.24%. The company had revenue of $250.00 million during the quarter, compared to analyst estimates of $264.04 million. During the same quarter last year, the firm posted ($0.08) earnings per share. The firm’s revenue was up 1.6% on a year-over-year basis.
A number of equities analysts have issued reports on the company. Barrington Research reiterated a “buy” rating and issued a $7.00 price objective on shares of Opko Health in a report on Monday, November 12th. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Friday, November 30th. Finally, ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Opko Health has a consensus rating of “Buy” and an average target price of $9.50.
In related news, CEO Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock in a transaction dated Friday, December 28th. The stock was purchased at an average cost of $3.13 per share, for a total transaction of $313,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $9,605,816.63. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders have bought 640,000 shares of company stock valued at $2,024,500 over the last 90 days. Corporate insiders own 42.74% of the company’s stock.
Large investors have recently modified their holdings of the company. Diversified Trust Co bought a new stake in Opko Health in the 4th quarter worth about $30,000. Wells Fargo & Company MN increased its holdings in Opko Health by 4.3% in the 3rd quarter. Wells Fargo & Company MN now owns 337,868 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 13,905 shares in the last quarter. Douglas Lane & Associates LLC bought a new stake in Opko Health in the 4th quarter worth about $42,000. Strs Ohio increased its holdings in Opko Health by 20.5% in the 3rd quarter. Strs Ohio now owns 88,600 shares of the biotechnology company’s stock worth $306,000 after buying an additional 15,100 shares in the last quarter. Finally, RK Asset Management LLC increased its holdings in Opko Health by 1.8% in the 3rd quarter. RK Asset Management LLC now owns 1,044,893 shares of the biotechnology company’s stock worth $3,615,000 after buying an additional 18,875 shares in the last quarter. Hedge funds and other institutional investors own 26.20% of the company’s stock.
OPK traded up $0.08 during trading on Monday, reaching $3.80. The stock had a trading volume of 2,678,746 shares, compared to its average volume of 5,644,035. The company has a current ratio of 0.91, a quick ratio of 0.78 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -13.10 and a beta of 1.97. Opko Health has a one year low of $2.34 and a one year high of $6.40.
About Opko Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
See Also: How mutual funds make money
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.